PhaseBio Pharmaceuticals (Research Triangle Park, NC) a development-stage biopharma company focused on elastin-like fusion proteins for improved expression and purification of biological, closed a $25M Series B financing. Participants include New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson Development Corp. and Fletcher Spaght Ventures.

Apnex Medical (St. Paul, MN) a clinical-stage medical device company developing an implantable treatment for moderate-to-severe obstructive sleep apnea, closed a $14M Series B financing. Participants include Domain Associates, New Enterprise Associates and Polaris Venture Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications, closed a $8M Series B financings, bringing the total round to $40M. Participants include New Enterprise Associates, Bay City Capital, Amgen Ventures, Astellas Venture Partners, MPM Capital and Kleiner Perkins Caufield and Byers.
Note: 2009 Year-in-Review Trend Analysis Coming 15 [...]

Zyngenia (Rockville, MD) a pre-clinical stage biotherapeutics company focused on multi-specific antibodies for oncology and autoimmune disorders, closed a $10M Series A financing. Particpants include New Enterprise Associates.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

TriVascular (Santa Rosa, CA) a clinical-stage medical device company focused on transluminally placed endovascular stent grafts for abdominal and thoracic aortic disease, closed a $30M Series B financing. Participants include New Enterprise Associates, Delphi Ventures, MPM Capital and Kearny Venture Partners.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb